RRC ID 86577
著者 Alhasan H, Terkawi MA, Matsumae G, Ebata T, Tian Y, Shimizu T, Nishida Y, Yokota S, Garcia-Martin F, M Abd Elwakil M, Takahashi D, Younis MA, Harashima H, Kadoya K, Iwasaki N.
タイトル Inhibitory role of Annexin A1 in pathological bone resorption and therapeutic implications in periprosthetic osteolysis.
ジャーナル Nat Commun
Abstract There is currently no therapy available for periprosthetic osteolysis, the most common cause of arthroplasty failure. Here, the role of AnxA1 in periprosthetic osteolysis and potential therapeutics were investigated. Reducing the expression of AnxA1 in calvarial tissue was found to be associated with increased osteolytic lesions and the osteolytic lesions induced by debris implantation were more severe in AnxA1-defecient mice than in wild-type mice. AnxA1 inhibits the differentiation of osteoclasts through suppressing NFκB signaling and promoting the PPAR-γ pathway. Administration of N-terminal-AnxA1 (Ac2-26 peptide) onto calvariae significantly reduced osteolytic lesions triggered by wear debris. These therapeutic effects were abrogated in mice that had received the PPAR-γ antagonist, suggesting that the AnxA1/PPAR-γ axis has an inhibitory role in osteolysis. The administration of Ac2-26 suppressed osteolysis induced by TNF-α and RANKL injections in mice. These findings indicate that AnxA1 is a potential therapeutic agent for the treatment of periprosthetic osteolysis.
巻・号 13(1)
ページ 3919
公開日 2022-7-7
DOI 10.1038/s41467-022-31646-0
PII 10.1038/s41467-022-31646-0
PMID 35798730
PMC PMC9262976
MeSH Animals Annexin A1* / genetics Annexin A1* / metabolism Bone Resorption* / pathology Mice Mice, Inbred C57BL Osteoclasts / metabolism Osteolysis* / etiology Osteolysis* / pathology Peroxisome Proliferator-Activated Receptors / metabolism
IF 12.121
リソース情報
ヒト・動物細胞 THP-1(RCB1189)